1724 related articles for article (PubMed ID: 31354695)
1. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
5. Clinical tolerance in allogeneic hematopoietic stem cell transplantation.
Roncarolo MG; Gregori S; Lucarelli B; Ciceri F; Bacchetta R
Immunol Rev; 2011 May; 241(1):145-63. PubMed ID: 21488896
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
7. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
8. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
9. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
10. The potential role of γδ T cells after allogeneic HCT for leukemia.
Handgretinger R; Schilbach K
Blood; 2018 Mar; 131(10):1063-1072. PubMed ID: 29358176
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
13. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation and cellular therapy.
Kolb HJ
HLA; 2017 May; 89(5):267-277. PubMed ID: 28371460
[TBL] [Abstract][Full Text] [Related]
15. Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies.
Dotti G
Curr Opin Hematol; 2015 Nov; 22(6):489-96. PubMed ID: 26335421
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation.
Schneidawind D; Meyer E
Front Immunol; 2020; 11():523. PubMed ID: 32265940
[No Abstract] [Full Text] [Related]
17. Donor-derived CD19-targeted T cells in allogeneic transplants.
Magnani CF; Biondi A; Biagi E
Curr Opin Hematol; 2015 Nov; 22(6):497-502. PubMed ID: 26390165
[TBL] [Abstract][Full Text] [Related]
18. In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation.
Busca A; Aversa F
Expert Opin Biol Ther; 2017 Nov; 17(11):1401-1415. PubMed ID: 28846051
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
20. Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.
Di Ianni M; Olioso P; Giancola R; Santarone S; Natale A; Papalinetti G; Villanova I; Baldoni S; Di Tommaso A; Bonfini T; Accorsi P; Di Bartolomeo P
Int J Hematol; 2017 Dec; 106(6):860-864. PubMed ID: 28721499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]